On the heels of a PhI­II im­plo­sion, can­cer biotech Molo­gen is turned over to the liq­uida­tor

The 31 staffers left at Ger­man biotech Molo­gen are now work­ing for a liq­uida­tor. And the fo­cus now is on find­ing buy­ers for any­thing it has left that can be sold.

Molo­gen filed for in­sol­ven­cy a few days ago, months af­ter its lead drug — the TLR9 ag­o­nist lefi­tolimod — failed bad­ly in Phase III.

Back in Au­gust the com­pa­ny re­port­ed that their drug pro­duced a near mir­ror im­age re­sult for me­di­an over­all sur­vival in com­par­i­son to the con­trol group in a Phase III. Their OS rate was 22 months when the drug was used as a sec­ond-line ther­a­py for col­orec­tal can­cer. That com­pared to 21.9 months for the com­par­i­son group. And sec­ondary end­points didn’t pro­vide any rea­son to hope for some­thing bet­ter.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.